Immediate Angioplasty for Stroke From Severe Brain Artery Narrowing
Tests immediate angioplasty in adults with stroke caused by severe brain artery narrowing.
Plain-language title generated from the registry record
Registry title: Immediate Angioplasty For Acute Ischemic Stroke With Severe Intracranial Atherosclerotic Stenosis
Key facts
- Where
- Guangzhou and Shenzhen, ChinaSee the 2 sites
Where in China
- Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityGuangzhou, ChinaTaking people
- Shenzhen Hospital of Southern Medical UniversityShenzhen, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Trial code
- NCT06437600
- Record updated
- 25 May 2025
- Original description
A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial that aims to evaluate the effect of immediate angioplasty (with or without stenting) for acute ischemic stroke (AIS) with severe intracranial atherosclerotic stenosis (ICAS) in improving the 90-day functional outcome.Read full original descriptionShow less
Immediate Angioplasty For Acute Ischemic Stroke With Severe Intracranial Atherosclerotic Stenosis (MAGIC): A Multicenter, Prospective, Open-label, Blinded Endpoint, Randomized Controlled Trial
A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial that aims to evaluate the effect of immediate angioplasty (with or without stenting) for acute ischemic stroke (AIS) with severe intracranial atherosclerotic stenosis (ICAS) in improving the 90-day functional outcome.
Inclusion: Aged 18 years or older; Diagnosed with AIS and baseline NIHSS ≥6; Pre-stroke mRS ≤2; Time from symptom onset to randomization ≤ 24 hours; the onset time refers to "Last Known Well" (LKW); Non-contrast CT ASPECTS score ≥6; CTA confirmed severe ICAS (70-99%) of the intracranial segment of the internal carotid artery, or M1 or M2 segment of the middle cerebral artery, and is presumed to be responsible for the stroke; Informed consent signed by the patient or authorized representative.
Exclusion: Concomitant intracranial tumor (except for meningioma <10mm) or arteriovenous malformation; Hemorrhagic stroke within the past 90 days; Cerebrovascular conditions such as vasculitis, moya-moya disease, arterial inflammatory stenosis, vasospasm, traumatic dissection, etc; Known cardiac thrombus source (e.g., atrial fibrillation, patent foramen ovale, infective endocarditis); Intracranial hemorrhage confirmed by CT or MRI; Severe allergy to contrast (non-mild rash allergy) or absolute contraindication to iodine contrast; Any active bleeding or recent bleeding in the last 1 month; Anticipated life expectancy <3 months (e.g., malignancy, severe cardiopulmonary disease, etc.); Any condition that, in the judgment of the investigator, makes the patient unsuitable for this study or where this study may impose a significant risk to the patient (e.g., inability to understand and/or comply with study procedures and/or follow-up due to psychiatric disorders, cognitive or emotional impairment); INR >1.7 when using warfarin; coagulation dysfunction or uncorrectable bleeding factors; Platelet count <50×10\^9/L; Known severe renal insufficiency with glomerular filtration rate <30 ml/min or blood creatinine >220 μmol/L (2.5 mg/dl); Normal diameter of the culprit vessel <2.0 mm; Isolated perforator artery infarction (except for combined cortical hypoperfusion); Severe calcification at the stenosis site, where expected residual stenosis ≤50% cannot be achieved with procedure; Women who are pregnant or breastfeeding; Participation in other intervention clinical trials; Aortic dissection; Severe vascular tortuosity, difficult access for intervention, or inability to complete endovascular treatment; SBP>185 mmHg or DBP>110 mmHg refractory to treatment.